Stereotactic radiosurgery and hypofractionated stereotactic radiotherapy: normal tissue dose constraints of the central nervous system.

Abstract:

:Single-fraction stereotactic radiosurgery (SRS) and hypofractionated stereotactic radiotherapy (SRT) are radiation planning and delivery techniques used for the treatment of intracranial and spine/spinal cord tumors and targets. For cranial SRS and SRT, critical normal tissues/structures include the brainstem, cranial nerves, cochlea and normal brain parenchyma. For spine SRS/SRT, critical normal tissues/structures include the spinal cord, cauda equina as well as neighboring organs. This paper reviews clinical studies investigating central nervous system dose tolerances after cranial or spinal SRS/SRT. The impact of dose, volume, fractionation, and other relevant clinic-pathologic variables are discussed, as are limitations of the published data.

journal_name

Cancer Treat Rev

journal_title

Cancer treatment reviews

authors

Milano MT,Usuki KY,Walter KA,Clark D,Schell MC

doi

10.1016/j.ctrv.2011.04.004

subject

Has Abstract

pub_date

2011-11-01 00:00:00

pages

567-78

issue

7

eissn

0305-7372

issn

1532-1967

pii

S0305-7372(11)00066-1

journal_volume

37

pub_type

杂志文章,评审
  • Cardiovascular effects of breast cancer radiotherapy.

    abstract::Cardiac toxicity has been implicated as the primary reason for excess non-breast cancer mortality in early breast cancer radiotherapy studies. Refinements in radiotherapy techniques have allowed for a considerable reduction of this risk in the majority of breast cancer patients. Recent large population-based studies c...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2007.07.011

    authors: Senkus-Konefka E,Jassem J

    更新日期:2007-10-01 00:00:00

  • Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence.

    abstract::Hepatocellular carcinoma (HCC) is the most common primary liver cancer, representing the sixth leading cause of cancer and the third leading cause of cancer-related mortality. Patient stratification and treatment allocation are based on tumor stage, liver function, and performance status. According to the Barcelona Cl...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.11.002

    authors: Raoul JL,Forner A,Bolondi L,Cheung TT,Kloeckner R,de Baere T

    更新日期:2019-01-01 00:00:00

  • Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.

    abstract::Patients with solid tumours are at risk of impaired bone health from metastases and cancer therapy-induced bone loss (CTIBL). We review medical management of bone health in patients with solid tumours over the past 30 years, from first-generation bisphosphonates to the receptor activator of nuclear factor κB ligand (R...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2019.05.003

    authors: von Moos R,Costa L,Gonzalez-Suarez E,Terpos E,Niepel D,Body JJ

    更新日期:2019-06-01 00:00:00

  • Low dose cyclophosphamide: Mechanisms of T cell modulation.

    abstract::Cyclophosphamide is considered one of the most successful chemotherapy drugs and is listed on the World Health Organisations List of Essential Medicines. Since its initial synthesis in 1958, it has been widely used to treat a range of cancers but its use has been declining due to the advent of platinum based and other...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2015.11.005

    authors: Madondo MT,Quinn M,Plebanski M

    更新日期:2016-01-01 00:00:00

  • Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer.

    abstract::The majority of stage III NSCLC patients managed with a combination of radiotherapy and chemotherapy will develop a locoregional or distant relapse. Concomitant radiochemotherapy allows for improved local control but has no impact on extrathoracic recurrences. To ameliorate this inefficiency the concept of consolidati...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.04.001

    authors: Skrzypski M,Jassem J

    更新日期:2018-05-01 00:00:00

  • Biliary tract cancers: molecular profiling as a tool for treatment decisions. A literature review.

    abstract::Biliary tract cancer is a quite rare disease; despite recent significant advances in imaging modalities, most of the patients have advanced disease at presentation thus making radical surgery not feasible. Many different chemotherapeutic regimens have been investigated in small uncontrolled studies, with generally dis...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2006.03.003

    authors: Berardi R,Scartozzi M,Freddari F,Squadroni M,Santinelli A,Bearzi I,Fabris G,Cascinu S

    更新日期:2006-08-01 00:00:00

  • Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors.

    abstract::Lung cancer represents the most common cause of brain dissemination. Oncogene-addicted (EGFR- and ALK-positive) non-small cell lung cancers (NSCLCs) are characterized by a unique metastatic neurotropism resulting in a particularly high incidence of brain metastases. The goal of optimal brain metastases management is t...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.10.011

    authors: Wrona A,Dziadziuszko R,Jassem J

    更新日期:2018-12-01 00:00:00

  • Interleukin-2 with and without LAK cells in metastatic renal cell carcinoma: the Lyon first-year experience in 20 patients.

    abstract::Thirty-one patients with metastatic renal cell carcinoma were seen at the Centre Léon Bérard from October 1987 to October 1988. According to our protocol, 11 were excluded leaving 20 in the study. The median age was 55 years (range 36 to 79 years). The median number of metastases was 9 (range 2 to 29) and the median n...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1016/0305-7372(89)90028-5

    authors: Philip T,Mercatello A,Negrier S,Philip I,Rebattu P,Kaemmerlin P,Gaspard M,Tognier E,Combaret V,Bijmann JT

    更新日期:1989-06-01 00:00:00

  • The emerging role of MET/HGF inhibitors in oncology.

    abstract::The N-methyl-N'-nitroso-guanidine human osteosarcoma transforming gene (MET) receptor tyrosine kinase and its ligand hepatocyte growth factor (HGF) control cellular signaling cascades that direct cell growth, proliferation, survival, and motility. Aberrant MET/HGF activation has been observed in many tumor types, can ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.ctrv.2013.02.001

    authors: Scagliotti GV,Novello S,von Pawel J

    更新日期:2013-11-01 00:00:00

  • Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): Literature review and case series from two Australian tertiary medical institutions.

    abstract::Peptide receptor radionuclide therapy (PRRT) is an important therapeutic option for somatostatin receptor (SSTR) positive metastatic and/or inoperable neuroendocrine tumours (NETs). However, in patients with poorly controlled carcinoid syndrome, it may lead to an acute flare of carcinoid symptoms or even carcinoid cri...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.03.002

    authors: Tapia Rico G,Li M,Pavlakis N,Cehic G,Price TJ

    更新日期:2018-05-01 00:00:00

  • Safety of cranial radiotherapy concurrent with tyrosine kinase inhibitors in non-small cell lung cancer patients: A systematic review.

    abstract::Recently, non-small cell lung cancer (NSCLC) has been partly subclassified into molecularly-defined oncogene "addicted" tumors for which targeted agents are available. Tyrosine kinase inhibitors (TKI) are currently approved for patients with an activating epidermal growth factor receptor (EGFR) mutation or anaplastic ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2015.05.005

    authors: Hendriks LE,Schoenmaekers J,Zindler JD,Eekers DB,Hoeben A,De Ruysscher DK,Dingemans AM

    更新日期:2015-07-01 00:00:00

  • Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: A systematic-review and framework for adjuvant radiotherapy.

    abstract:BACKGROUND:Radical cystectomy (RC) associated with pelvic lymph node dissection (PLND) is the most common local therapy in the management of non-metastatic muscle invasive bladder cancer (MIBC). Loco-regional recurrence (LRR), however, remains a common and important therapeutic challenge associated with poor oncologic ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.07.011

    authors: Sargos P,Baumann BC,Eapen L,Christodouleas J,Bahl A,Murthy V,Efstathiou J,Fonteyne V,Ballas L,Zaghloul M,Roubaud G,Orré M,Larré S

    更新日期:2018-11-01 00:00:00

  • Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials.

    abstract::Six major randomized clinical trials evaluating the role of taxanes in the adjuvant setting of breast cancer have demonstrated significant improvements in terms of efficacy in favour of the taxane treatment arm. In all cases, different anthracycline-based regimens were used as the control arm. Nevertheless, many clini...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2007.04.006

    authors: Estévez LG,Muñoz M,Alvarez I,Fernández Y,García-Mata J,Ruiz-Borrego M,Tusquets I,Seguí MA,Rodríguez-Lescure A,Adrover E,Lluch A

    更新日期:2007-08-01 00:00:00

  • Tolerability and safety of rituximab (MabThera).

    abstract::Rituximab, a human/mouse chimeric anti-CD20 antibody, has become part of standard therapy for patients with CD20-expressing B-cell lymphoma, and is currently under investigation for other indications including autoimmune diseases, in particular rheumatoid arthritis (RA). Its characteristic tolerability profile was est...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2005.05.007

    authors: Kimby E

    更新日期:2005-10-01 00:00:00

  • Neck lymph node metastases from unknown primary.

    abstract::Metastatic cervical carcinoma from unknown primary is a metastatic disease in the lymph nodes of the neck without any evidence of a primary tumour after appropriate investigation. The condition is rare and definite evidence is lacking for both diagnosis and treatment. In this review of the literature, we tried to draw...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2016.11.014

    authors: Arosio AD,Pignataro L,Gaini RM,Garavello W

    更新日期:2017-02-01 00:00:00

  • Adjuvant therapy in colon cancer: current status and future directions.

    abstract::The role of adjuvant chemotherapy in patients with stage III colon cancer is now well established and 5-FU/LV should be the reference regimen to which new drugs are tested against in the adjuvant setting. In stage II colon cancer, because the risk of recurrence is lower, any absolute benefit of chemotherapy is likely ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(02)00047-6

    authors: Chau I,Cunningham D

    更新日期:2002-10-01 00:00:00

  • In vivo antitumor activity of ilmofosine.

    abstract::Ilmofosine is a cytostatic/cytotoxic thioether phospholipid derivative. The in vivo anti-tumour activity of this compound was investigated in a methylcholanthrene (MethA)-induced fibrosarcoma and in the 3Lewis-lung carcinoma systems, respectively. Ilmofosine showed antineoplastic and antimetastatic properties at oral ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1016/0305-7372(90)90055-k

    authors: Herrmann DB,Pahlke W,Opitz HG,Bicker U

    更新日期:1990-09-01 00:00:00

  • Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma.

    abstract::Hodgkin lymphoma is a B cell derived malignancy characterized by a low number of tumor cells within an environment consisting of inflammatory cells. Recently, immune checkpoint blockade targeting the PD-1-PD-L1 axis has shown to be a great success in relapsed and refractory Hodgkin lymphoma patients. However, complete...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2019.101931

    authors: Veldman J,Visser L,Berg AVD,Diepstra A

    更新日期:2020-01-01 00:00:00

  • Radiotherapy-induced ear toxicity.

    abstract::Despite their particular functional consequences, radiotherapy-induced ear injuries remain under-evaluated and under-reported. These reactions may have acute or late character, may affect all structures of the hearing organ, and result in conductive, sensorineural or mixed hearing loss. Up to 40% of patients have acut...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(03)00066-5

    authors: Jereczek-Fossa BA,Zarowski A,Milani F,Orecchia R

    更新日期:2003-10-01 00:00:00

  • Anticancer drugs: estrophilic cisplatin derivatives.

    abstract::Our approach to develop platinum complexes with a selective effect on the hormone-dependent MC by exchanging the two NH3 groups of cisplatin by an 1,2-bis(4-hydroxy-phenyl)ethylenediamine derivative which possesses estrogenic activity, was successful. The most interesting compound of this new platinum complex series, ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1016/0305-7372(87)90018-1

    authors: Engel J,Schönenberger H,Lux F,Hilgard P

    更新日期:1987-12-01 00:00:00

  • Swallowing dysfunction in head and neck cancer patients treated by radiotherapy: review and recommendations of the supportive task group of the Italian Association of Radiation Oncology.

    abstract:PURPOSE:Dysphagia is a debilitating complication in head and neck cancer patients (HNCPs) that may cause a high mortality rate for aspiration pneumonia. The aims of this paper were to summarize the normal swallowing mechanism focusing on its anatomo-physiology, to review the relevant literature in order to identify the...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2012.04.002

    authors: Russi EG,Corvò R,Merlotti A,Alterio D,Franco P,Pergolizzi S,De Sanctis V,Ruo Redda MG,Ricardi U,Paiar F,Bonomo P,Merlano MC,Zurlo V,Chiesa F,Sanguineti G,Bernier J

    更新日期:2012-12-01 00:00:00

  • Maintenance treatment of recurrent ovarian cancer: Is it ready for prime time?

    abstract::Approximately 1% of women in the United States will be diagnosed with epithelial ovarian cancer (EOC) during their lifetime. It is most likely to present at a more advanced stage, requiring aggressive therapeutic measures, and most women will succumb to this illness. Due to advancements in therapy, the oncology commun...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.06.001

    authors: DiSilvestro P,Alvarez Secord A

    更新日期:2018-09-01 00:00:00

  • Differential expression of drug resistance following in vitro exposure of human tumour cell lines to fractionated X-irradiation.

    abstract::We have established that drug resistance can be expressed following in vitro exposure of tumour cells not only to antitumor drugs but also to fractionated X-irradiation. These data therefore suggest a biological basis for the clinical problem of drug resistance that can occur in patients with previously irradiated tum...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1016/0305-7372(90)90012-5

    authors: Hill BT,Whelan RD,Hosking LK,Bedford P,Dempke WC,Shellard SA

    更新日期:1990-12-01 00:00:00

  • Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options.

    abstract::Hepatocellular carcinoma (hepatocellular carcinoma, HCC) is the commonest primary liver cancer (80-90%) and represents the leading cause of cancer-related death, after lung and stomach cancer. The process of neoplastic transformation proceeds through the accumulation of mutations in the genes governing cell proliferat...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2010.08.001

    authors: Faloppi L,Scartozzi M,Maccaroni E,Di Pietro Paolo M,Berardi R,Del Prete M,Cascinu S

    更新日期:2011-05-01 00:00:00

  • Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms.

    abstract::Targeted therapies have unique toxicity profiles. Common adverse events include rash, diarrhea, hypertension, hypothyroidism, proteinuria, depigmentation, and hepatotoxicity. Some of these toxicities are caused by on-target, mechanism-associated effects, which can be stratified as to whether or not the targets are rel...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2014.05.003

    authors: Liu S,Kurzrock R

    更新日期:2014-08-01 00:00:00

  • Progress in the surgical treatment of malignant liver tumors in children.

    abstract::During the last decade, important progress has been made in the surgical treatment of malignant liver tumors in children. For hepatoblastoma, there is a general consensus for combining surgical resection with neoadjuvant (and adjuvant) chemotherapy. Long-term disease-free survival of around 85-90% can be achieved for ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2010.02.013

    authors: Otte JB

    更新日期:2010-06-01 00:00:00

  • Update on capecitabine alone and in combination regimens in colorectal cancer patients.

    abstract::Capecitabine is an orally administered fluoropyrimidine carbamate which has been developed as a prodrug of 5-FU with the goal to improve its tolerability and intratumoral drug concentration. The review aims to provide an evidence-based update of clinical trials investigating the clinical efficacy, adverse-event profil...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/S0305-7372(10)70020-7

    authors: Silvestris N,Maiello E,De Vita F,Cinieri S,Santini D,Russo A,Tommasi S,Azzariti A,Numico G,Pisconti S,Petriella D,Lorusso V,Millaku A,Colucci G

    更新日期:2010-11-01 00:00:00

  • Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors.

    abstract::The first-generation epidermal growth factor receptor tyrosine kinase inhibitors erlotinib and gefitinib have been incorporated into treatment paradigms for patients with advanced non-small cell lung cancer. These agents are particularly effective in a subset of patients whose tumors harbor activating epidermal growth...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2011.01.003

    authors: Giaccone G,Wang Y

    更新日期:2011-10-01 00:00:00

  • Rectal and colon cancer: Not just a different anatomic site.

    abstract::Due to differences in anatomy, primary rectal and colon cancer require different staging procedures, different neo-adjuvant treatment and different surgical approaches. For example, neoadjuvant radiotherapy or chemoradiotherapy is administered solely for rectal cancer. Neoadjuvant therapy and total mesorectal excision...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2015.06.007

    authors: Tamas K,Walenkamp AM,de Vries EG,van Vugt MA,Beets-Tan RG,van Etten B,de Groot DJ,Hospers GA

    更新日期:2015-09-01 00:00:00

  • A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma.

    abstract:BACKGROUND:We performed a systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy (NHT) in localised and locally advanced prostate cancer to assess the effectiveness of this therapy. METHODS:We searched MEDLINE, The Cochrane Library, Science Citation Index, LILACS and SIGLE for randomi...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.ctrv.2008.08.002

    authors: Shelley MD,Kumar S,Wilt T,Staffurth J,Coles B,Mason MD

    更新日期:2009-02-01 00:00:00